Avoiding hepatic veno-occlusive disease: What do we know and where are we going?

Bone Marrow Transplantation

Volumn 27, Issue 11, 2001, Pages 1113-1120

  Bearman, S I ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Stem cell transplantation; Toxicity; Veno occlusive disease

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; ACETYLCYSTEINE; ACROLEIN; ALTEPLASE; ANTICOAGULANT AGENT; ANTITHROMBIN III; BUSULFAN; CARBON MONOXIDE; CYCLOPHOSPHAMIDE; DEFIBROTIDE; DRUG METABOLITE; GLUTAMINE; GLUTATHIONE; HEPARIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; TUMOR NECROSIS FACTOR ALPHA; URSODEOXYCHOLIC ACID; VON WILLEBRAND FACTOR;

AREA UNDER THE CURVE; ARTICLE; BLEEDING; BLOOD CLOTTING; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL DAMAGE; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; ENDOTHELIUM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFLAMMATION; LIVER CELL; LIVER FIBROSIS; LIVER VENOOCCLUSIVE DISEASE; LUNG DIFFUSION CAPACITY; MEDIATOR; PATHOGENESIS; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM; WHOLE BODY RADIATION;

COMBINED MODALITY THERAPY; ENDOTHELIUM, VASCULAR; FEMALE; FIBRINOLYTIC AGENTS; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; MALE; TRANSPLANTATION CONDITIONING;

EID: 0034948756     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703014     Document Type: Article

References (79)

1. The syndrome of hepatic veno-occlusive disease after marrow transplantation
2. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients
3. Late onset veno-occlusive disease following high-dose chemotherapy and stem cell transplantation
4. Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: Incidence, risk factors, and outcome
5. Venocclusive disease of the liver. Development of a model for predicting fatal outcome after marrow transplantation
6. Treatment of severe veno-occlusive disease with defibrotide: Compassionate use results in efficacy without significant toxicity in a high risk population
7. Venocclusive disease of the liver after marrow transplantation: Histological correlates of clinical signs and symptoms
8. Increased platelet transfusion requirement is associated with multiple organ dysfunctions in patients undergoing hematopoietic stem cell transplantation
9. Plasma thrombopoietin levels in marrow transplant patients with veno-occlusive disease
10. Liver cell heterogeneity and liver function
11. Sublobular distribution of transferases and hydrolases associated with glucuronide, sulfate and glutathione conjugation in human liver
12. Dacarbazine toxicity in murine liver cells: A model of hepatic endothial injury and glutathione defense
13. Cellular target of cyclophosphamide toxicity in murine liver: Role of glutathione and site of metabolic activation
14. Support of sinusoidal endothelial cell glutathione prevents hepatic veno-occlusive disease in the rat
15. N-acetylcysteine for hepatic veno-occlusive disease after allogeneic stem cell transplantation
16. Glutamine preserves liver glutathione after lethal hepatic injury
17. Glutamine and vitamin E in the treatment of hepatic veno-occlusive disease following high-dose chemotherapy
18. Parenteral glutamine protects hepatic function during bone marrow transplantation
19. Hepatic veno-occlusive disease after bone marrow transplantation. Immunohistochemical identification of the material within occluded central venules
20. Naturally occuring anticoagulants and bone marrow transplantation: Plasma protein C predicts development of venocclusive disease of the liver
21. Predictive markers for hepatic veno-occlusive disease after hematopoietic stem cell transplantation in adults: A prospective single center study
22. High frequency of antithrombin 3 and protein C deficiency following autologous bone marrow transplantation for lymphoma
23. Multiple organ dysfunction syndrome in bone marrow transplantation
24. Relevance of proteins C and S, antithrombin III, von Willebrand factor, and factor VIII for the development of hepatic veno-occlusive disease in patients undergoing allogeneic bone marrow transplantation: A prospective study
25. Hypercoagulability in patients undergoing autologous or allogeneic BMT for hematological malignancies
26. Changes in the natural anticoagulants following bone marrow transplantation
27. Plasma levels of D-dimer and circulating endothelial adhesion molecules in veno-occlusive disease of the liver following allogeneic bone marrow transplantation
28. Ven-occlusive disease of the liver after allogeneic bone marrow transplantation in man
29. Regimen-related toxicity of a bulsulfan-cyclophosphamide conditioning regimen in 70 patients undergoing allogeneic bone marrow transplantation
30. Effects of oral contraceptives on hemostasis and thrombosis
31. Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation
32. A pilot study of continuous infusion heparin for the prevention of hepatic ven-occlusive disease after bone marrow transplantation
33. Prophylactic heparin does not prevent liver veno-occlusive disease following autologous bone marrow transplantation
34. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: A prospective, randomized trial
35. Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation
36. Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients
37. Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients
38. Tissue plasminogen activator (tPA) as therapy for hepatotoxicity following bone marrow transplantation
39. Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation
40. Antithrombin treatment of severe hepatic veno-occlusive disease in children with cancer
41. Multi-institutional emergency use of defibrotide in 75 patients post SCT with severe VOD and multisystem organ failure: Response without significant toxicity in a high risk population
42. Pharmacokinetics of busulfan: Correlation of veno-occlusive disease in patients undergoing bone marrow transplantation
43. Association of busulfan area under the curve with veno-occlusive disease following BMT
44. High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients
45. Graft rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics
46. Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation
47. Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients
48. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: A phase I study
49. Decreased incidence of and risk factors for hepatic veno-occlusive disease with an intravenous busulfan containing preparative regimen for hematopoietic stem cell transplantation
50. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation
51. Pentoxifylline, ciprofloxacin and prednisone failed to prevent transplant-related toxicities in bone marrow transplant recipients and were associated with an increased incidence of infectious complications
52. Cytokine gene expression in peripheral blood mononuclear cells during graft-versus-host disease after allogeneic bone marrow transplantation
53. Increased levels of soluble interleukin-2 receptor in veno-occlusive disease of the liver after allogenic bone marrow transplantation
54. Does early treatment with high-dose methylprednisolone alter the course of hepatic regimen-related toxicity?
55. Increased plasma level of vascular endothelial glycoprotein thrombomodulin as an early indicator of endothelial damage in bone marrow transplantation
56. Endothelium and bone marrow transplantation
57. Elevation of tissue factor pathway inhibitor (TFPI), thrombomodulin (TM) and plasminogen activator inhibitor-1 (PAI-1) levels in stem cell transplant (SCT)-associated veno-occlusive disease
58. Parameters of the fibrinolytic system in patients undergoing BMT: Elevation of PAI-1 in veno-occlusive disease
59. Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation
60. Vascular endothelial lesion in patients undergoing bone marrow transplantation
61. Predictive value of pulmonary function tests before marrow transplantation
62. Association of pulmonary function testing abnormalities and severe veno-occlusive disease of the liver after marrow transplantation
63. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies
64. Transcriptional regulation of the biglycan gene
65. Hepatic stellate cells (Ito cells) in veno-occlusive disease of the liver after allogeneic bone marrow transplantation
66. Monitoring of veno-occlusive disease after bone marrow transplantation by serum amino-propeptide of type III procollagen
67. Serum procollagen type III is an early and sensitive marker for veno-occlusive disease of the liver in children undergoing bone marrow transplantation
68. N-terminal peptide of type III procollagen: A marker for the development of hepatic veno-occlusive disease after BMT and a basis for determining the timing of prophylactic heparin
69. Circulating markers of hepatic fibrosis predict evolution of venocclusive disease after marrow transplantation
70. Recipient tumor necrosis factor-alpha and interleukin-10 gene polymorphisms associate with early mortality and acute graft-versus-host disease severity in HLA-matched sibling bone marrow transplants
71. Tumor necrosis factor d3 allele predicts for organ dysfunction after allogeneic blood stem cell transplantation
72. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial
73. The Japanese multi-center open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation
74. Study of the pharmacological effect of the bile salt, sodium scymnol sulfate, from Rhizopriondon acutus. II. Prophylactic effect of scymnol on lesion development in a rat peripheral arterial occlusion model
75. Role of cytokines in ethanol-induced cytotoxicity in vitro in Hep G2 cells
76. Transjugular intrahepatic portosystemic shunt for the management of severe venocclusive disease following bone marrow transplantation
77. Successful treatment of hepatic veno-occlusive disease in a peripheral blood progenitor cell transplant patient with a transjugular intrahepatic portosystemic stent-shunt (TIPS)
78. Transjugular intrahepatic portosystemic shunting (TIPS) for treatment of severe hepatic veno-occlusive disease
79. Transjugular intrahepatic portosystemic shunt (TIPS) for severe veno-occlusive disease of the liver following bone marrow transplantation